At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

- Full year 2020 net sales grew to $441.8 million , a 30% increase over 2019 - Upcoming PDUFA action date of April 3, 2021 for supplemental New Drug Application for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis SAN DIEGO --(BUSINESS
-   Educational resources help caregivers of the estimated 2.4 million people living with dementia-related hallucinations and delusions identify and discuss symptoms SAN DIEGO --(BUSINESS WIRE)--Feb. 19, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of
SAN DIEGO --(BUSINESS WIRE)--Feb. 18, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences: 10 th Annual SVB Leerink Global Healthcare Conference Fireside Chat Presentation: Friday, February 26, 2021 at 10:40 a.m.